The core idea is deceptively simple: if the immune system clears foreign nanoparticles before they can do their work, disguise them as something the body already tolerates. The most extensively studied disguise is the red blood cell membrane. Human erythrocytes circulate for roughly 120 days, largely because they display CD47, a surface protein that transmits a “don’t eat me” signal to macrophages, along with band 3 and glycophorins that suppress opsonization and complement activation. When nanoparticles are cloaked in RBC membrane, they inherit these properties, dramatically extending circulation half-life and protecting encapsulated mRNA or peptide antigens from serum nucleases and proteases. Hybrid RBC-lipid nanoparticle platforms have shown improved mRNA protection, prolonged antigen expression, and enhanced dendritic cell uptake, while RBC-coated PLGA particles loaded with tumor peptides have generated stronger cytotoxic T lymphocyte responses in preclinical tumor models.

Exosomes, the nanoscale vesicles between 30 and 150 nanometers that cells naturally secrete to communicate with one another, offer a second biomimetic strategy with a different immunological personality. Their membranes carry tetraspanins and integrins that promote selective uptake by dendritic cells, and their origin matters enormously. Tumor-derived exosomes ferry a broad repertoire of tumor-associated antigens and neoantigens that mirror the parental tumor, but they can also smuggle immunosuppressive cargo such as PD-L1, TGF-beta, and regulatory microRNAs that blunt T-cell responses. Dendritic cell-derived exosomes, by contrast, come pre-loaded with MHC-peptide complexes and CD80/CD86 co-stimulatory molecules capable of priming both CD4 and CD8 T cells without requiring live dendritic cells. The catch is manufacturing: donor heterogeneity, variable cargo composition, and purification methods that differ wildly in yield and purity make GMP-grade standardization a formidable barrier.

Fully synthetic coatings sidestep some of that unpredictability. Artificial lipid bilayers and polymer shells can be tuned for antigen density, ligand spacing, endosomal escape, and release kinetics, and they can be functionalized with mannose for dendritic cell targeting, TLR agonists such as CpG or MPLA for innate activation, or checkpoint modulators like anti-PD-1 peptides. pH-sensitive and enzyme-responsive linkers now allow cargo release triggered by the acidic, enzyme-rich tumor microenvironment itself. Perhaps most striking are artificial antigen-presenting cells, polymeric scaffolds displaying MHC-I-peptide complexes and co-stimulatory ligands, which have outperformed natural dendritic cells at activating antigen-specific CD8 T cells both in vitro and in vivo. Hybrid systems that combine RBC membranes with exosomal or tumor-derived components aim to capture the best of both worlds: long circulation plus tumor homing and cross-presentation.

On the payload side, the review distinguishes two complementary modalities. Peptide nanovaccines deliver defined tumor epitopes chosen for strong MHC binding and minimal expression in healthy tissue, with neoantigens prioritized over shared antigens to avoid central tolerance. The authors’ own prior work illustrates the approach: survivin epitope variants delivered in PLGA nanoparticles drove potent CTL responses, BCMA peptide-loaded nanoparticles enhanced dendritic cell delivery in multiple myeloma models, and STEAP peptide nanovaccines inhibited tumor growth in vivo. mRNA nanovaccines take the opposite tack, encoding full-length antigens or multiple epitopes so that dendritic cells manufacture the antigen themselves, activating both CD4 and CD8 arms. Because mRNA does not integrate into the genome and carries intrinsic adjuvanticity through TLR3, TLR7/8, and RIG-I sensing, it offers a favorable safety profile, though poor endosomal escape and dose-dependent inflammation remain stubborn bottlenecks.

The COVID-19 pandemic supplied an unplanned clinical laboratory for these questions. The global mRNA-LNP rollout revealed that reactogenicity is dose-dependent, driven by innate recognition of ionizable lipids and mRNA structures, and that maximal inflammation does not equal optimal immune priming. Subtle structural differences in ionizable lipids markedly alter endosomal escape, biodistribution, and cytokine induction. For oncology, where patients are often immunosuppressed with altered pharmacokinetics, these lessons argue for individualized dose optimization, careful immune monitoring, and lipid engineering tailored specifically to cancer vaccination rather than borrowed wholesale from infectious disease.

Personalization is where the field is converging. Next-generation sequencing, mass spectrometry-based immunopeptidomics, and AI-guided epitope prediction now allow neoantigen discovery pipelines that move from tumor biopsy to individualized vaccine design in clinically relevant timelines. Autologous platforms go further, using patient-derived RBC, leukocyte, tumor cell, or exosome membranes so that even the nanoparticle surface reflects the patient’s biology, with tumor membrane coatings enabling homotypic binding to the originating cancer. The clinical signal is already visible: in the phase II KEYNOTE-942 trial, the personalized mRNA vaccine mRNA-4157 combined with pembrolizumab reduced recurrence risk by 44 percent and extended median progression-free survival from 16 to 23 months in resected high-risk melanoma, while BioNTech’s BNT111, targeting four melanoma-associated antigens, has demonstrated induction of both new and boosted pre-existing T-cell responses, albeit with a modest objective response rate that underscores interpatient variability.

Combination strategies may prove decisive. Biomimetic nanovaccines can prime T cells before checkpoint blockade, and sequencing studies suggest priming before PD-1 or CTLA-4 inhibition consistently outperforms simultaneous delivery. Co-delivery of antigens with TLR7/8, TLR9, or STING agonists within the same vesicle synchronizes innate and adaptive activation, while macrophage-targeted formulations can repolarize immunosuppressive M2 tumor-associated macrophages toward a pro-inflammatory M1 phenotype. Radiotherapy adds another layer, inducing immunogenic cell death that releases tumor antigens and damage-associated molecular patterns, activating the cGAS-STING pathway, and in rare but increasingly frequent cases producing abscopal responses in which nanovaccine-amplified immunity attacks metastases far from the irradiated site.

The translational obstacles are nonetheless sobering. Every personalized batch requires individualized sequencing, formulation, and quality control under time pressure dictated by fast-growing tumors. Patient-derived materials resist standardization, regulatory classification is murky because these products straddle biologics, cell therapies, and devices, and cold-chain logistics complicate distribution. The authors argue that modular microfluidic manufacturing, AI- and large-language-model-assisted neoantigen design, machine learning models that predict optimal nanoparticle physicochemistry, computer vision quality control, and digital twins of production pipelines could compress timelines and enforce batch consistency. Adaptive trial designs, including N-of-1 and Bayesian schemes, may be needed to evaluate vaccines that are by definition unique to each recipient, while immune-related response criteria replace conventional RECIST measurements that miss immunotherapy’s delayed kinetics.

What emerges from the review is a field in transition from clever chemistry to systems engineering. The mechanistic questions remain open, including how specific membrane compositions steer nanoparticles toward cross-presenting cDC1 dendritic cells versus degradative macrophage pathways, and which glycan signatures determine whether a coating stimulates or tolerizes. But the trajectory is clear: biomimetic coatings that borrow the body’s own camouflage, payloads scripted from each tumor’s mutanome, and AI-driven optimization loops that connect antigen discovery, formulation, manufacturing, and clinical feedback are converging into a unified platform. If the manufacturing and regulatory bottlenecks can be solved, the cancer vaccine may finally graduate from decades of sporadic promise into a routine pillar of precision oncology.

Subject of Research: Biomimetic and personalized nanovaccine platforms for cancer immunotherapy

Article Title: Biomimetic and personalized nanovaccines in cancer immunotherapy: Design innovations, translational challenges, and future directions

Article References: Xu, S., Yang, H., Minev, B., & Ma, W. (2026). Biomimetic and personalized nanovaccines in cancer immunotherapy: Design innovations, translational challenges, and future directions. Journal of Advanced Research, 88, 1137-1158. https://doi.org/10.1016/j.jare.2026.01.070

Image Credits: AI Generated

DOI: 10.1016/j.jare.2026.01.070

Keywords: nanovaccines, cancer immunotherapy, biomimetic nanoparticles, mRNA vaccines, neoantigens, red blood cell membrane, exosomes, lipid nanoparticles, immune checkpoint blockade, dendritic cells, personalized medicine, STING agonists

The appeal of nanomaterials lies in physics rather than chemistry alone. When matter is reduced to dimensions below roughly 100 nanometers, quantum effects and an enormous surface-area-to-volume ratio transform its behavior, dramatically enhancing electrical, magnetic, optical, and catalytic properties compared with the same material in bulk form. In water treatment, this translates into far greater capacity to capture and degrade contaminants. Aquaculture effluent is a complicated cocktail: total suspended solids, fecal matter and uneaten feed, phosphorus and nitrogen, ammonia, therapeutic drugs, and antifouling chemicals. The review identifies four principal classes of nanomaterials for tackling this burden: metal-containing nanoparticles, carbonaceous nanomaterials such as carbon nanotubes, zeolites, and dendrimers, each exploiting distinct mechanisms of adsorption, reduction, or catalytic oxidation.

Silver nanoparticles have emerged as the most intensively studied disinfection agents. Their antimicrobial power stems from a multi-pronged attack: the particles adhere to bacterial cell walls, penetrate them, and alter permeability, while silver ions interact with sulfur- and phosphorus-containing cellular components, inactivate enzymes by binding thiol groups, disrupt DNA replication, and trigger the release of reactive oxygen species. Laboratory studies cited in the review found that nanosilver at just 1 milligram per liter can suppress roughly 80 percent of a microbial population. Crucially, the authors caution against dosing water directly, since silver can bioaccumulate in cultured fish destined for human consumption. A safer strategy, they suggest, is coating filtration equipment with silver nanoparticles, allowing disinfection without exposing the animals themselves to the metal.

Nano zero-valent iron particles represent a second workhorse of nanoscale water remediation. These tiny iron particles act as powerful reducing agents, transferring electrons from their surfaces to pollutants and converting them into less harmful forms. Their redox activity, combined with adsorption and precipitation, has been harnessed to remove halogenated organic compounds, dyes, phenols, heavy metals, phosphates, and nitrates. One striking example is the treatment of hexavalent chromium, a highly carcinogenic contaminant: the iron nanoparticles reduce it to chromium(III), which precipitates as a far more stable hydroxide. Researchers have also documented effective lead removal using stabilized zero-valent iron, though concerns about the persistence of these particles in treated systems have driven efforts to immobilize them within porous support materials.

Zinc and iron oxide nanoparticles round out the water-treatment toolkit. Zinc oxide nanoparticles combine strong photocatalytic and oxidative capabilities with low cost and environmental compatibility, and their performance can be boosted by doping with metal ions, semiconductors, or reduced graphene oxide. Comparative studies found that zero-valent zinc outperformed iron, aluminum, and nickel nanoparticles in degrading octachlorodibenzo-p-dioxin, one of the most notorious persistent organic pollutants. Magnetic iron oxides, including magnetite, maghemite, and hematite, serve as efficient sorbents for heavy metals; magnetite nanosorbents have shown a maximum adsorption capacity of 36 milligrams of lead per gram of material, and their superparamagnetism allows easy recovery from treated water. Titanium dioxide, meanwhile, acts as a broad-spectrum photocatalyst, generating reactive oxygen species under even low ultraviolet light to destroy gram-positive and gram-negative bacteria, fungi, and viruses. In China, a sintered ceramic nanomaterial called Nano-863, prized for its light absorption and heat resistance, is already being used commercially to improve water quality for shrimp farming and to curb algal blooms.

Beyond water quality, the review highlights a less obvious frontier: fish reproduction. Captive fish often suffer reproductive dysfunction, and conventional hormonal therapies to induce spawning are undermined by the short half-life of gonadotropin-releasing hormone, which is rapidly degraded by enzymes in the pituitary, kidney, and liver. Repeated injections work but stress the animals. Nanoparticle carriers offer an elegant workaround. In common carp, researchers conjugated the hormone LHRH to chitosan nanoparticles and chitosan-gold nanoparticles, achieving sustained hormone release and fertilization rates of 87 percent and 83 percent respectively, compared with 74 percent in controls. In walking catfish, chitosan nanoparticles loaded with pheromones kept serum hormone levels elevated far longer than injections. Oral delivery of GnRHa via chitosan nanoparticles in goldfish, fed every three days over 40 days, prolonged hormone elevation and significantly increased egg diameter, while PLGA nanoparticles loaded with aromatase inhibitors have been used to produce monosex populations of tilapia and guppies.

Feeding efficiency is another target. Aquafeed is perishable, and its water-soluble components leach into ponds, driving pollution and nutrient loss while inflating costs. Nanotechnology addresses this by encapsulating active ingredients, protecting them until they reach the fish’s intestine. Nanoparticle-enriched feeds have demonstrably improved growth, survival, feed conversion ratio, specific growth rate, weight gain, blood parameters, and immune responses. Selenium nanoparticles enhanced growth and larval development in Nile tilapia, Asian sea bass, and gilthead sea bream at species-specific doses; iron nanoparticles upregulated growth-related genes in goldfish and improved muscle protein in catfish; and chitosan nanoparticles boosted immunity and survival in tilapia, common carp, and giant tiger prawns.

Disease management may be where nanotechnology delivers its most consequential impact. Antibiotic resistance is now documented throughout aquaculture, with tetracycline-, streptomycin-, and erythromycin-resistant Aeromonas hydrophila isolated from tilapia farms, alongside resistant strains of Staphylococcus aureus, Vibrio, Yersinia ruckeri, and Edwardsiella. Nanoparticles offer an alternative: engineered antibacterial surfaces, nanosensors that detect pathogens in water, and nano-encapsulated medicines delivered through feed. Diagnostic applications are already proving their worth. Magnetic nanoparticles coated with antibodies change color from red to blue when they bind viral antigens, enabling rapid detection of nervous necrosis virus in groupers, while unmodified gold nanoparticles have been used in similar colorimetric assays for spring viremia of carp and koi herpesvirus. Electrical nanosensors can now detect a single virus particle, and wireless tracking nanosensors permit individual fish health monitoring through data analysis.

Nanovaccines tackle the central dilemma of fish immunization: oral vaccines are destroyed by gastric digestion, while injections stress the animals. Polymer and lipid nanoparticles shield antigens from degradation in the gastrointestinal tract and deliver them intact to provoke mucosal, humoral, and cellular immunity. Challenge trials with nanovaccines against Listonella anguillarum succeeded in Asian carp and rainbow trout, chitosan-based oral nanovaccines protected tilapia against columnaris disease, and chitosan-coated membrane vesicles strengthened immunity against Piscirickettsia salmonis in zebrafish. Biosensors extend this precision medicine approach to physiology itself: enzyme-based immunosensors measure cortisol in fish blood to quantify stress, ranking stressors from air exposure to nitrite, while wireless implantable sensors transmit real-time blood glucose readings from swimming fish to receivers on shore.

The review is candid about the risks. Because of their minute size, nanoparticles readily cross cell membranes, and their chemical reactivity generates reactive oxygen species and free radicals that can cause inflammation, protein damage, and DNA deterioration. Silver nanoparticles smaller than 10 nanometers inflicted significantly more kidney and gill damage in rainbow trout than particles exceeding 35 nanometers, copper nanoparticles harmed liver, brain, and gill function in Mozambique tilapia, and zero-valent iron proved more toxic to embryonic medaka than to adults, underscoring the heightened vulnerability of early life stages. Nano waste, the authors warn, constitutes a novel form of pollution requiring careful tracking through food chains. Regulatory frameworks, including World Health Organization guidelines on manufactured nanomaterials, remain a work in progress, and the authors call for sustained investment, public-private partnerships, and technology transfer to developing nations. With emerging tools such as multi-omics toxicology and personalized fish health assessment on the horizon, they conclude that responsible integration of nanotechnology could help aquaculture meet global protein demands without compromising the ecosystems on which it depends.

Subject of Research: Applications of nanotechnology in sustainable aquaculture and fish health management

Article Title: Interventions of nanotechnology-based applications as a novel tool for sustainable aquaculture and fish medicines

Article References: Riyaz, R., Iqbal, G., Gargotra, P., & Ganie, P. A. (2025). Interventions of nanotechnology-based applications as a novel tool for sustainable aquaculture and fish medicines. Blue Biotechnology, 2(1), Article 12. https://doi.org/10.1186/s44315-025-00034-w

Image Credits: AI Generated

DOI: 10.1186/s44315-025-00034-w

Keywords: nanotechnology, aquaculture, nanoparticles, water treatment, fish health, nanovaccines, nanosensors, antibiotic resistance, fish nutrition, nanotoxicology, sustainability, chitosan

The scale of the problem is sobering. Lower respiratory infections consistently rank among the leading causes of infectious mortality worldwide, and the latest Global Burden of Disease analyses confirm that the burden has not meaningfully receded. Without prompt treatment, bacterial pneumonia can trigger acute inflammatory cascades that spiral into sepsis and multi-organ failure. Standard antibiotic therapy, meanwhile, is being undermined from two directions at once: the rise of multidrug-resistant pathogens such as carbapenem-resistant Enterobacteriaceae, methicillin-resistant Staphylococcus aureus, and resistant strains of Pseudomonas aeruginosa and Klebsiella pneumoniae, and the sheer difficulty of getting drugs to the site of infection inside the lung.

That second problem is less famous but just as consequential. The lung is a fortress of physiological barriers designed to keep foreign particles out. Inhaled or systemically delivered antibiotics must contend with viscoelastic mucus layers, pulmonary surfactants, an acidic microenvironment at sites of infection, oxidative stress from reactive oxygen species, and hypertonic waste accumulation. Each of these can degrade, trap, or deactivate drug molecules before they ever reach bacteria embedded in alveoli or hiding inside biofilms. The review emphasizes that these barriers are not merely passive obstacles; they actively shape the pharmacokinetics of inhaled and intravenous therapies, which is why so many promising antibiotics underperform in the clinic.

Nanotechnology enters the picture as a way to turn these barriers from liabilities into triggers. Nanocarriers, typically particles ranging from tens to a few hundred nanometers, can be engineered to protect their cargo during transit, penetrate mucus, and release their payload only when specific conditions are met. The review categorizes the main platforms into inorganic systems, polymeric nanoparticles, extracellular vesicle-based carriers, and hybrid nanoplatforms, each with distinct strengths. Inorganic materials such as gold and silver nanoparticles, mesoporous silica, and metal-organic frameworks offer tunable surfaces and, in some cases, intrinsic antimicrobial activity. Silver nanoparticles, for example, generate reactive oxygen species that damage bacterial membranes, while metal-organic frameworks can act as catalytic nanoreactors that deplete bacterial antioxidant defenses such as glutathione.

Polymeric carriers, including particles made of poly(lactide-co-glycolide) and chitosan, have proven particularly valuable for pulmonary delivery because they can be formulated into inhalable dry powders and engineered for mucoadhesion or mucus penetration. One highlighted strategy uses muco-adhesive chitosan-coated polyphenol nanoparticles to sustain the pulmonary delivery of polymyxin B, a last-resort antibiotic whose systemic use is limited by nephrotoxicity. Localizing such drugs directly to infected lung tissue with nanoparticles could preserve antibacterial potency while sparing the kidneys, and studies cited in the review suggest that precise delivery to the lung infection microenvironment also reduces collateral damage to the gut microbiome, a common and underappreciated side effect of systemic antibiotics.

Perhaps the most technically elegant section of the review concerns stimuli-responsive targeting. Rather than releasing drugs continuously, these nanocarriers exploit the distinctive chemistry of infected lungs as a built-in switch. pH-sensitive systems discharge their cargo in the acidic microenvironment surrounding bacterial colonies. Reactive-oxygen-species-responsive polymers disintegrate amid the oxidative burst of inflamed tissue. Enzyme-responsive designs release antimicrobial peptides only when bacterial proteases or beta-lactamases cleave their protective shells, a strategy that also helps neutralize resistance enzymes. External triggers add another layer of control: ultrasound-activated nanoantibiotics have been shown to mediate sequential therapy against MRSA lung infections, while magnetothermal and piezoelectric sonodynamic platforms generate localized antibacterial effects in inhaled formulations. Light-responsive systems, long explored in oncology, are now being adapted for antimicrobial phototherapy of the airways.

Targeting itself comes in three flavors, the review explains. Passive targeting exploits the enhanced permeability and retention effect, in which nanoparticles accumulate at inflamed, leaky tissue. Active targeting decorates particle surfaces with ligands, such as mannose or hyaluronic acid, that bind receptors on infected cells or bacterial surfaces. Biomimetic targeting goes further still: nanoparticles cloaked in neutrophil or macrophage membranes inherit the natural homing behavior of immune cells and can even recognize bacteria directly. Neutrophil membrane-coated nanoparticles have shown enhanced antimicrobial activity against resistant K. pneumoniae, and homotypic-recognizing nanovesicles have been engineered to hunt intracellular bacteria. In one striking example from the broader literature, nanoparticle-modified microrobots have delivered antibiotics in vivo to treat acute bacterial pneumonia, hinting at a future where active propulsion complements passive circulation.

Beyond killing bacteria, the review devotes substantial attention to immune modulation, reflecting a growing recognition that pneumonia mortality often stems from the host’s own inflammatory response as much as from the pathogen itself. Nanocarriers can deliver anti-inflammatory agents such as the IKK inhibitor TPCA-1 via platelet-derived extracellular vesicles to calm cytokine storms, or dexamethasone directly to alveolar macrophages to reshape the immune microenvironment. Extracellular vesicles derived from mesenchymal stromal cells have demonstrated therapeutic effects in severe pneumonia models, and tracheal epithelial cell exosomes carrying microRNA-21-5p have been shown to inhibit macrophage pyroptosis, a fiery form of cell death that fuels lung inflammation. Nanovaccines represent the preventive frontier: manganese-based nanoparticle vaccines, outer membrane vesicle coatings, and multiepitope chitosan-PLGA formulations against Acinetobacter baumannii all illustrate how nanoscale engineering can train immunity against the most dangerous respiratory pathogens.

Gene therapy rounds out the therapeutic arsenal. Lipid nanoparticles, the same platform technology behind mRNA vaccines, are being loaded with siRNA and delivered by nebulization to silence bacterial virulence factors in Staphylococcus aureus pneumonia, while CRISPR-Cas systems packaged in nanocarriers have been used to cure plasmids carrying carbapenemase genes from resistant bacteria. Antimicrobial peptide-derived lipid nanoparticles enabling lung-targeted mRNA therapy for multidrug-resistant pneumonia point toward a modality in which the lung itself is instructed to produce therapeutic proteins on site. Combined with in situ CAR-macrophage engineering demonstrated in sepsis models, these approaches suggest that nanomedicine may eventually treat pneumonia not by delivering a drug, but by reprogramming the host’s cellular machinery.

The authors are candid about the obstacles between laboratory promise and bedside reality. Carrier heterogeneity makes batch-to-batch consistency difficult, particularly for biologically derived extracellular vesicles. Pulmonary-specific barriers demand formulation strategies that differ fundamentally from those used in cancer nanomedicine, and the toxicity of inhaled metal nanoparticles remains an open question requiring careful biokinetic study. Clinical scalability, regulatory pathways, and the cost of manufacturing complex biomimetic systems all loom large. Yet the trajectory is clear: liposomal ciprofloxacin has already completed phase 3 trials for chronic Pseudomonas lung infections, and nebulized liposomal amikacin has advanced through phase 2 studies in cystic fibrosis patients, proving that inhaled nanotherapeutics can navigate clinical development. The review’s expert opinion is that the convergence of targeted, stimuli-responsive, and immune-modulating nanocarriers offers a genuine pathway to precision therapy for bacterial pneumonia, a disease that has waited far too long for its nanotechnology moment.

Subject of Research: Nanotherapeutic drug delivery systems for the targeted and precision treatment of bacterial pneumonia

Article Title: Nanotherapeutic delivery systems in bacterial pneumonia: targeting, responsiveness, and immune modulation toward precision therapy

Article References: Krishnamoorthi, R., Wang, Y.-T., Lin, C.-Y., Alalaiwe, A., & Fang, J.-Y. (2026). Nanotherapeutic delivery systems in bacterial pneumonia: targeting, responsiveness, and immune modulation toward precision therapy. Journal of Pharmaceutical Investigation. https://doi.org/10.1007/s40005-026-00829-y

Image Credits: AI Generated

DOI: 10.1007/s40005-026-00829-y

Keywords: bacterial pneumonia, nanocarriers, drug delivery, antimicrobial resistance, stimuli-responsive nanoparticles, extracellular vesicles, immunomodulation, pulmonary drug delivery, antimicrobial peptides, nanovaccines, lipid nanoparticles, metal-organic frameworks